Table 1

Patient characteristic at baseline.

Active LN* (n = 47)


Age, years

Mean ± SE

32.90 ± 1.29

Range, years

26-39

Sex, number

Female

50 (96)

Duration of SLE, years

Mean ± SE

5.90 ± 0.62

Renal-SLEDAI score

Median

12

Range

8-12

Prednisone use, number (%)

47 (90)

Median dosage, mg/day

16.00

Dosage range, mg/day

7.5-50

Immunosuppressive drug use

Intravenous methylprednisolone

3

Intravenous cyclophosphamide

6

Mycophenolate mofetil

6

Azathioprine

1

Hydroxychloroquine

2

Extrarenal manifestation, number (%)

12 (23)

BLyS, ng/mla

1.32 ± 0.15

APRIL, ng/mla

4.10 ± 0.30

Serum creatinine, mg/dl

1.06 ± 0.08

Proteinuria, g/day

Urinary erythrocyte count, per high power field

3.59 ± 0.31

50.84 ± 11.96

Immunological parametersa

C3 (normal range: 70-140 mg/dL)

60.86 ± 6.05,

ANA, titer

731.20 ± 606.29

Anti-dsDNA, titer

351.74 ± 73.76

Histological parameters

Activity score

7.83 ± 0.70

Chronicity score

3.01 ± 0.37


*Includes only lupus nephritis class III or IV by ISN/RPS 2003 criteria, ‡ renal-SLEDAI (Systemic Lupus Erythematosus Disease Activity Score) uses four endpoints as follows: UPCI or 24-hour urine protein ≥0.5 g/day, urinary RBCs ≥5/HPF, urinary WBCs ≥5/HPF and urinary cellular casts ≥1/HPF; and the maximal point was set at 16. aData are expressed as mean ± SE. ANA, antinuclear antibody; APRIL, a proliferation-inducing ligand; BlyS, B lymphocyte activation protein; HPF, high power field; LN, lupus nephritis; RBC, red blood cells; SLE, systemic lupus erythematous; WBC, white blood cells.

Treamtrakanpon et al. Arthritis Research & Therapy 2012 14:R252   doi:10.1186/ar4095

Open Data